...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International Journal of General Medicine >A review of the pharmacoeconomics of eletriptan for the acute treatment of migraine
【24h】

A review of the pharmacoeconomics of eletriptan for the acute treatment of migraine

机译：依曲曲坦治疗偏头痛的药效学研究进展

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract: Migraine is a commonly occurring, chronic disorder that can cause significant disability. Eletriptan, a selective serotonin 5-hydroxytryptamine 1 receptor subtype B/D (5-HT1B/1D) agonist, is a clinically effective treatment for moderate to severe migraine. The objective of this literature review was to summarize the available data on the pharmacoeconomics of eletriptan relative to other triptans. Articles meeting the following three criteria were included in the review: 1) contained pharmacoeconomic data on a marketed dose of eletriptan; 2) included data on at least one other comparator triptan; and 3) was in English. A MEDLINE? search yielded a total of eight studies (from the European Union [n=5] and from the USA [n=3]) across multiple regions. Seven of the studies examined the pharmacoeconomics of eletriptan relative to other triptans, and a further study examined the health care costs of eletriptan 40 mg versus sumatriptan 100 mg. Eletriptan 40 mg was among a group of triptans, including rizatriptan 10 mg and almotriptan 12.5 mg, demonstrating the greatest cost-effectiveness. This result held across different definitions of efficacy (2 hours pain-free, sustained pain-free, and sustained pain-free with no adverse events) and also held when cost-effectiveness models accounted for second doses and use of rescue medication, management of adverse events, and productivity loss, in addition to drug acquisition costs. Only limited head-to-head comparator data were available. The majority of pharmacoeconomic studies utilized the same set of efficacy and/or tolerability data, and indirect costs were rarely included despite the fact that the majority of per capita migraine costs are attributable to indirect costs. In summary, although the market is now dominated by generics, eletriptan 40 mg is among the most clinically and cost-effective oral triptans available for the management of acute migraine. Increased effectiveness/efficacy of eletriptan may necessitate a lesser need for other migraine treatments and/or switching to other triptans.
机译：摘要：偏头痛是一种常见的慢性疾病，可能导致严重的残疾。 Eletriptan是一种选择性的5-羟色胺5-羟色胺1受体B / D亚型（5-HT1B / 1D）激动剂，是中度至重度偏头痛的临床有效治疗方法。这篇文献综述的目的是总结依曲曲坦相对于其他曲普坦的药物经济学的可用数据。符合以下三个标准的文章包括在本评价中：1）包含有关依曲曲坦市售剂量的药物经济学数据; 2）包含至少一个其他比较剂曲普坦的数据; 3）是英文。 MEDLINE？搜索结果得出了多个地区的八项研究结果（来自欧盟[n = 5]和来自美国[n = 3]）。七项研究检查了依曲曲坦相对于其他曲普坦的药物经济学，进一步的研究研究了依曲曲坦40 mg与舒马曲坦100 mg的保健费用。依曲曲坦40 mg是一组曲普坦中的一种，其中包括利扎曲普坦10 mg和阿莫曲普坦12.5 mg，这表明其最大的成本效益。该结果涵盖了不同的功效定义（2小时无痛，持续无痛和持续无痛且无不良事件），并且在成本效益模型考虑了第二剂量和急救药物的使用，不良事件和生产力损失，以及药品购买成本。只有有限的头对头比较器数据可用。大多数药物经济学研究都使用相同的功效和/或耐受性数据集，尽管大多数人均偏头痛费用可归因于间接费用，但很少包含间接费用。总而言之，尽管现在市场上以仿制药为主导，但依曲普坦40 mg是可用于治疗急性偏头痛的最临床和最具成本效益的口服曲普坦之一。依曲曲坦疗效/功效的提高可能需要减少对其他偏头痛治疗和/或改用其他曲普坦的需求。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号